Brief: Jagsonpal Pharmaceuticals Receives Warning Letter From USFDA
21/02/2025 12:57
Feb 21 (Reuters) - Jagsonpal Pharmaceuticals Ltd
JGSN.NS :
* JAGSONPAL PHARMACEUTICALS LTD - RECEIVES WARNING LETTER
FROM
USFDA
* JAGSONPAL PHARMACEUTICALS LTD - USFDA CITES CGMP
DEVIATION,
REGISTRATION, AND LISTING VIOLATION
* JAGSONPAL PHARMACEUTICALS: USFDA WARNING REGARDING
OBSERVATIONS
DURING INSPECTION OF CONTRACT MANUFACTURING FACILITY OF
JAGSONPAL
* JAGSONPAL PHARMACEUTICALS - FINANCIAL IMPACT INCLUDES SALE
OF 35
MILLION RUPEES
Source text: ID:nBSEbDdYHY
Further company coverage: JGSN.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Jagsonpal Pharmaceuticals
See all newsIndia's Jagsonpal Pharma jumps on purchase of wellness portfolio of Group Pharma
Brief: Jagsonpal Pharmaceuticals To Buy Wellness Portfolio Of Group Pharmaceuticals
Brief: Jagsonpal Pharmaceuticals Passes Buy-Back Resolution
Brief: Jagsonpal Pharmaceuticals Gets Order For Tax Demand Of 48.2 Million Rupees
India's Jagsonpal Pharmaceuticals jumps after plan to buyback shares